Three-year follow-up phase 3 data provide additional information on efficacy, durability and safety of investigational LUXTURNA™ (voretigene neparvovec) in patients with biallelic RPE65-mediated inherited retinal disease - Spark Therapeutics
Accessed September 20, 2020 at: